Bristol-Myers’ High Risk Opdivo Lung Cancer Study Shows Challenges Of Clinical Trials

Merck clearly took the safer route with its NSCLC clinical trial design with Keytruda by selecting a subset of patients most likely to benefit from its drug. But, from a scientific standpoint, the BMS study has importantly contributed to the body of knowledge being generated by these exciting immune-oncology drugs and will help guide oncologists in how best to treat NSCLC patients. http://www.forbes.com/sites/johnlamattina/2016/08/08/bristol-myers-high-risk-opdivo-lung-cancer-study-shows-challenges-of-clinical-trials/